Sign In
Buy GTHX
$7.15
+0 (+0%)
At Close: Dec 16, 2024
G1 Therapeutics to Present at Investor Conferences in March 2020
12:00pm, Monday, 24'th Feb 2020
RESEARCH TRIANGLE PARK, N.C., Feb. 24, 2020 -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that the company will present corporate.
G1 Therapeutics (GTHX) Scheduled to Post Earnings on Wednesday
11:22am, Monday, 24'th Feb 2020
G1 Therapeutics (NASDAQ:GTHX) is set to post its quarterly earnings results after the market closes on Wednesday, February 26th. Analysts expect G1 Therapeutics to post earnings of ($0.97) per share f
California Public Employees Retirement System Grows Position in G1 Therapeutics Inc (NASDAQ:GTHX)
09:54am, Sunday, 23'rd Feb 2020
California Public Employees Retirement System lifted its holdings in shares of G1 Therapeutics Inc (NASDAQ:GTHX) by 15.9% during the 4th quarter, according to its most recent Form 13F filing with the
G1 Therapeutics to Provide Fourth Quarter and Full Year 2019 Corporate and Financial Update on February 26, 2020
12:00pm, Wednesday, 19'th Feb 2020
RESEARCH TRIANGLE PARK, N.C., Feb. 19, 2020 -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and.
G1 Therapeutics (NASDAQ:GTHX) Downgraded to Strong Sell at BidaskClub
05:54am, Wednesday, 19'th Feb 2020
G1 Therapeutics (NASDAQ:GTHX) was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research report issued on Tuesday, BidAskClub reports. Several other
G1 Therapeutics to Participate in BTIG Targeted Therapeutics Conference on February 24, 2020
12:00pm, Tuesday, 18'th Feb 2020
RESEARCH TRIANGLE PARK, N.C., Feb. 18, 2020 -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Medical Officer Raj Malik,.
G1 Therapeutics to Participate in BTIG Targeted Therapeutics Conference on February 24, 2020
12:00pm, Monday, 17'th Feb 2020
RESEARCH TRIANGLE PARK, N.C., Feb. 17, 2020 -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Medical Officer Raj Malik,.
G1 Therapeutics to Participate in BTIG Targeted Therapeutics Conference on February 24, 2020
12:00pm, Monday, 17'th Feb 2020
RESEARCH TRIANGLE PARK, N.C., Feb. 17, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced...
Zacks: Brokerages Anticipate G1 Therapeutics Inc (NASDAQ:GTHX) Will Announce Earnings of -$0.97 Per Share
03:20am, Thursday, 13'th Feb 2020
Wall Street analysts expect G1 Therapeutics Inc (NASDAQ:GTHX) to post earnings of ($0.97) per share for the current quarter, according to Zacks. Zero analysts have made estimates for G1 Therapeutics�
G1 Therapeutics (NASDAQ:GTHX) Stock Rating Upgraded by ValuEngine
04:42am, Tuesday, 11'th Feb 2020
G1 Therapeutics (NASDAQ:GTHX) was upgraded by ValuEngine from a “hold” rating to a “buy” rating in a research note issued on Monday, ValuEngine reports. Several other equities analysts have al
G1 Therapeutics (NASDAQ:GTHX) Upgraded to "Sell" at BidaskClub
07:34am, Monday, 10'th Feb 2020
BidaskClub upgraded shares of G1 Therapeutics (NASDAQ:GTHX) from a strong sell rating to a sell rating in a report issued on Thursday morning, BidAskClub reports. GTHX has been the topic of several ot
G1 Therapeutics to Participate in Guggenheim Health Talks: Oncology Day on February 13, 2020
12:00pm, Thursday, 06'th Feb 2020
RESEARCH TRIANGLE PARK, N.C., Feb. 06, 2020 -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark.
Companies Like G1 Therapeutics (NASDAQ:GTHX) Are In A Position To Invest In Growth
10:02am, Tuesday, 04'th Feb 2020
We can readily understand why investors are attracted to unprofitable companies. For example, although...
G1 Therapeutics (NASDAQ:GTHX) Rating Increased to Buy at ValuEngine
08:16am, Saturday, 01'st Feb 2020
G1 Therapeutics (NASDAQ:GTHX) was upgraded by investment analysts at ValuEngine from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Saturday, ValuEng
Turning Point Therapeutics Names Garry Nicholson to Its Board of Directors
02:00pm, Thursday, 23'rd Jan 2020
Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Garry Nicholson to
